First Line Therapy with Fludarabine Combinations in 42 Patients with Either Post Myelodysplastic Syndrome or Therapy Related Acute Myeloid Leukaemia

References

• Dann E. J., Rowe J. M. Biology and therapy of secondary leukemias. ISH-EHA educational program book 1998; 114–120
   Google Scholar
• Hoyle C. F., De Bastos M., Wheatley K., Sherrington P. D., Fisher P. J., Rees J. K. H., Gray R., Hayhoe F. G. J. AML associated with previous cytotoxic therapy or myeloproliferative disorders: results from the MRC's 9th AML trial. British Journal of Haematology 1989; 72: 45–53
   PubMed Web of Science ®Google Scholar
• Gajewski J. L., Winston G. H., Nimer S. D., Hirji K. F., Gekelman L., Jacobs A. D., Champlin R. E. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. Journal of Clinical Oncology 1989; 7: 1637–1645
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Gooley T. A., Schoch G., Anasetti C., Bensinger W. I., Clift R., Hanser J. A., Sanders J. E., Storb R., Appelbaum F. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89: 2578–85
   PubMed Web of Science ®Google Scholar
• De Witte T., Biezen A., Hermans J., Labopin M., Runde V., Or R., Meloni G., Mauri S. B., Carella A., Apperley J., Gratwohl A., Laporte J. P. For the chronic and acute leukemia working party of the European Group for Blood and Marrow Transplantation Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 1997; 90: 3853–3857
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkett W., Gandhi V., Rios M. B., Kantarjian H., Keating M. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myeloid leukemia. Leukemia and Lymphoma 1993; 9: 343–350
   PubMed Web of Science ®Google Scholar
• Estey E., Thall P., Andreef M., Beran M., Kantarjian H., O'Brien S., Escudier S., Robertson L. E., Koller C., Komblau S., Pierce S., Freireich E., Deisseroth A., Keating M. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology 1994; 12: 671–678
   PubMed Web of Science ®Google Scholar
• Visani G., Tosi P., Zinzani P. L., Manfroi S., Ottaviani E., Testoni N., Clavio M., Cenacchi A. R., Gamberi B., Carrara P., Gobbi M., Tura S. FLAG (Fludarabine + High dose cytarabine + G-CSF) an effective and tolerable protocol for the treatment of “poor risk” acute myeloid leukemias. Leukemia 1994; 8: 1842–1846
   PubMed Web of Science ®Google Scholar
• Parker J. E., Pagliuca A., Mijovic A., Cullis J. O., Czepulkowski B., Rassam S. M. B., Samaratunga I. R., Grace R., Gover P. A., Mufti G. J. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor -risk myelodysplastic syndromes and acute myeloid leukemia. British Journal of Haematology 1997; 99: 939–944
   PubMed Web of Science ®Google Scholar
• Estey E. H., Thall P. F., Pierce S., Cortes J., Beran M., Kantarjian H., Keating M. J., Andreef M., Freireich E. Randomized phase II study of Fludarabine + Cytosine Arabinoside + Idarubicin All-trans Retinoic Acid Granulocyte Colony — Stimulating Factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478–84
   PubMed Web of Science ®Google Scholar
• Gandhi V., Huang P., Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leukemia and Lymphoma 1994; 14(suppl 2)3–9
   PubMed Web of Science ®Google Scholar
• Plunkett W., Gandhi V., Huang P., Robertson L. E., Yang L. Y., Gregoire V., Estey E., Keating M. Fludarabine: pharmacokinetics, mechanisms of action and rationales for combination therapies. Seminars in Oncology 1993; 20(suppl 7)2–12
   PubMedGoogle Scholar
• Leith C. P., Kopecky K. J., Godwin J., McConnell T., Slovak M., Chen I. M., Head D. R., Appelbaum F. R., Willman C. Acute myeloid leukemia in the elderly: assessment of multidrug resistence (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 9: 3323–3329
   Google Scholar
• Kantarjian H. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematological Oncology Clinic North America 1993; 7: 81–107
   PubMed Web of Science ®Google Scholar
• De Witte T., Suciu S., Peetrmans M., Fenaux P., Strijckmans P., Hayat M., Jaksic B., Selleslag D., Zittoun R., Dardenne M., Solbu G., Zwierzina H., Muus P. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organization for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9: 1805–1811
   PubMed Web of Science ®Google Scholar
• Gardin C., Chaibi P., De Revel T., Rousselot P., Turlure P., Miclea J. M., Nedellec G., Dombret H. Intensive chemotherapy with idarubicin. cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy related acute myelogenous leukemia. Leukemia 1997; 11: 16–21
   PubMed Web of Science ®Google Scholar
• Fenaux P., Morel P., Rose C., Lai J. L., Jouet J. P., Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology 1991; 77: 497–501
   PubMed Web of Science ®Google Scholar
• De Witte T., Suciu S., Boogaerts M., Labar B., Archimbaud E., Aul C., Selleslag D., Ferrant A., Weijermans P., Mandelli F., Amadori S., Jehn U., Muus P., DeMuynck H., Dardenne M., Willemze R., Gratwohl A., Apperley J. The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS and AML following MDS. Blood 1996, suppl 1: 454a, abs 1806
   Google Scholar
• Clavio M., Carrara P., Miglino M., Pierri I., Canepa L., Balleari E., Gatti A. M., Cerri R., Celesti L., Vallebella E., Sessarego M., Patrone F., Ghio R., Damasio E., Gobbi M. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81: 513–520
   PubMed Web of Science ®Google Scholar
• Estey E., Thall P., Beran M., Kantarijan H., Pierce S., Keating M. Effect of diagnosis (Refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia on outcome of AML-type chemotherapy. Blood 1997; 8: 2969–2977
   Google Scholar
• Bernasconi C., Alessandrino E. P., Bernasconi P., Bonfichi M., Lazzarino M., Canevari A., Castelli G., Brusamolino E., Pagnucco G., Castagnola C. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high risk myelodysplasia syndromes or secondary acute myeloid leukaemia evolving from MDS. British Journal of Haematology 1998; 102: 678–683
   PubMed Web of Science ®Google Scholar
• Freireich E. J., Cork A., Sass S. A., McCresdie K. B., Keating M. J., Estey E., Kantarjian H., Trujillo J. M. Cytogenetics for detection of MRD in acute myeloblastic leukemia. Leukemia 1992; 6: 500–506
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M., Haase D., Buske C., Hiddeman W., Wormann B. Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission. Leukemia 1999; 13: 386–392
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Cassileth P. A., Head D. R., Schiffer C. A., Bennett J. M., Bloomfield C. D., Brunning R., Gale R. P., Grever M. R., Keating M. J., Sawitsky A., Stass S., Weinstein H., Woods W. G. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Lowenberg B., Suciu S., Archimbaud E., Ossenkoppele G., Verhoef G. E. G., Vellenga E., Wijermans P., Berneman Z., Dekker A. W., Stryckmans P., Schouten H., Jehn U., Muus P., Sonneveld P., Dardenne M., Zittoun R. On behalf of EORTC-LCG and HOV. O. N. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and treatment of cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952–2961
   PubMed Web of Science ®Google Scholar
• Godwin J. E., Kopecky K. J., Head D. R., Willman C. L., Leith C., Hynes H., Balcerzac S. P., Appelbaum F. R. A double blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031). Blood 1998; 91: 3607–3615
   PubMed Web of Science ®Google Scholar
• Seiter K., Feldman E. J., Halicka H. D., Traganos F., Darzynkiewicz Z., Lake D., Ahmed T. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of Clinical Oncology 1997; 1: 44–51
   Google Scholar
• Estey E. H. New agents for the treatment of acute myelogenous leukemia, focus on topotecan and retinoids. Leukemia 1998; 12(suppl 1)13–15
   PubMedGoogle Scholar
• Runde V., De Witte T., Arnold R., Gratwohl A., Hermans J., Van Biezen A., Niederwieser D., Labopin M., Walter-Noel M. P., Bacigalupo A., Jacobsen N., Ljungman P., Carreras E., Kolb H. J., Aul C., Apperley J. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplantation 1998; 21: 255–261
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Anasetti C., Appelbaum F. R., Schoch G., Gooley T. A., Hansen J. H., Buckner C. D., Sanders J. E., Sullivan K. M., Storb R. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukemia. British Journal of Haematology 1996; 93: 59–67
   PubMed Web of Science ®Google Scholar
• Demuynck H., Delforge M., Verhoef G. E. G., Zachee P., Vandenberghe P., Van Den Berghe H., Boogaerts M. A. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. British Journal of Haematology 1996; 92: 351–359
   PubMed Web of Science ®Google Scholar
• Carella A. M., Dejana A., Lerma E., Podestà M., Benvenuto F., Chimirri F., Parodi C., Sessarego M., Prencipe E., Frassoni F. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy related acute myelogenous leukemia. British Journal of Haematology 1996; 95: 127–130
   PubMed Web of Science ®Google Scholar
• Aversa F., Tabilio A., Velardi A., Cunningham I., Falzetti F., Ruggeri L., Barbabietola G., Aristei C., Latini P., Reisner Y., Martelli M. F. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New England Journal of Medicine 1998; 339: 1186–1193
   PubMed Web of Science ®Google Scholar
• Slavin S., Nagler A., Naparstek E., Kapelushnik Y., Aker M., Cividalli G., Varadi G., Kirschbaum M., Ackerstein A., Samuel S., Amar A., Brautbar C., Ben-Tal O., Eldor A., Or R. Nonmyeloabiative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 1998; 91: 756–763
   PubMed Web of Science ®Google Scholar